NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Wednesday that its fourth quarter revenues fell 23 percent year over year, largely due to a drop in sample accessions compared to same quarter last year.

For the three months ended Dec. 31, the company reported that its Q4 revenues fell to $995,226, compared to $1.3 million for Q4 2016. This included $61,000 from development services testing and $935,000 from commercial tests.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.